Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Bright Minds Biosciences Inc.의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Bright Minds Biosciences Inc. 주요 수익원은 Partner Brands이며, 최신 수익 발표에서 수익은 583,400,000입니다. 지역별로는 United States이 Bright Minds Biosciences Inc.의 주요 시장이며, 수익은 2,599,800,000입니다.
Bright Minds Biosciences Inc.은 수익성이 있나요?
no, 최신 재무제표에 따르면 Bright Minds Biosciences Inc.의 순손실은 $-12입니다.